RESEARCHNEWS
ASTRAZENECA REPORTS TOP-LINE RESULTS FROM THE BRILINTA EUCLID TRIAL IN PATIENTS WITH PERIPHERAL
ARTERY DISEASE AstraZeneca has announced top-line results from the EUCLID trial. Brilinta (ticagrelor) did not demonstrate a benefit over clopidogrel in a symptomatic peripheral artery disease (PAD) patient population and therefore did not meet the primary endpoint of the trial.
SMARTPHONES COULD SPREAD INFECTION, NEW
RESEARCH SHOWS New research from disinfection and decontamination specialists, Sanondaf UK has revealed that mobile phones can present a significant risk of spreading infection in the workplace.
A survey carried out by the journal of Clinical Microbiology and Infection found that mobile phones present a substantial infection risk, with evidence of viruses in 38.5% of devices. The research, undertaken in a French hospital, found that mobile phones used by hospital staff were found to harbour viruses that cause stomach upsets and lung infections. It was also revealed that a fifth of staff did not clean their hands after handling their phones.
Scientists took swabs from mobile and cordless phones used daily by 114 doctors and nurses at Saint- Etienne University Hospital in Saint-Priest-en-Jarez, France. The most widespread contamination was from rotavirus, discovered on 39 out of 109 phones, which can cause vomiting and diarrhoea. Respiratory syncytial virus genetic material was found on three phones, and evidence of metapneumovirus was on one.
twitter.com/TomorrowsLabs
Both of these viruses are associated with lung infections, which in high- risk patients may be severe.
Stuart White, from Sanondaf UK, commented: “These results are quite alarming, and I think will be mirrored across many businesses. The survey found that 64% of workers used their mobile phones during patient care, with 20% of them admitting they had never carried out any hand hygiene procedures, either before or after using their phone.
“It’s something that many of us do not think about, but it’s something that businesses need to be aware of, particularly if you are in a caring profession, such as hospitals, care homes or nurseries. Workplace infection can be spread in a variety of different ways, with the best cleaners in the world unable to catch everything. Businesses lose many man hours a year to illness, which equates to a lot of money being wasted. These businesses need to put steps in place now to protect workers from infection.”
Sanondaf are specialists in disinfection and decontamination. Its specialist fogging product is proven to kill 99.99% of all hazardous viruses, bacteria, fungi or any other micro-organism.
www.sanondaf.co.uk
The EUCLID trial included 13,885 patients in 28 countries and is the largest cardiovascular (CV) outcomes trial to date conducted exclusively in symptomatic patients with PAD. It evaluated the treatment of Brilinta 90mg tablets twice daily versus clopidogrel 75mg once daily for the prevention of atherothrombotic events (a composite of cardiovascular death, heart attack or ischaemic stroke). The primary endpoint of the trial was the time to first occurrence of any such event.
Based on preliminary analyses, safety data is consistent with the known safety profile of Brilinta.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The proven benefits of Brilinta in acute coronary syndrome and post- myocardial infarction patients are established and remain unchanged. We are disappointed that the EUCLID trial results showed Brilinta did not demonstrate a benefit over clopidogrel in this specific symptomatic PAD population.”
Full results from the EUCLID trial are expected to be presented at the American Heart Association Scientific Sessions in New Orleans, Louisiana in November 2016.
www.astrazeneca.com Tomorrow’s Laboratories | 7
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44